What does NovaBay Pharmaceuticals do?
We have developed innovative product candidates targeting the treatment or prevention of a wide range of infections in hospital and non-hospital environments. We have discovered and is developing a class of non-antibiotic anti-infective compounds, which we have named Aganocide compounds, which are based upon small molecules that are generated by white blood cells to defend the body against invading pathogens. We believe that Aganocide compounds could form a platform on which to create a variety of products to address differing needs in the treatment and prevention of not only bacterial and viral infections, but also Staphylococcus aureus (including resistant strains known as MRSA) without developing resistance, a serious problem that invariably plagues all antibiotics. We have entered into a licensing and research collaboration agreement with Alcon Laboratories, Inc. for use of the Aganocide compounds in the eye, ear and sinus, and in contact lens solutions. We also have a license agre
